

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. Cancelled
2. (Currently Amended) A sustained-release drug delivery device comprising a structural element and a drug reservoir, wherein the drug reservoir comprises a coating applied to the surface of the structural element and wherein the coating comprises an inorganic mesoporous oxide with ~~The sustained-release drug delivery device of claim 4 wherein the mesoporous oxide possesses~~ substantially continuously interconnected channels.
3. (Original) The sustained-release drug delivery device of claim 2 wherein the majority of the interconnected channels have a diameter of between 1-100 nm.
4. (Original) The sustained-release drug delivery device of claim 3 wherein the majority of the interconnected channels have a diameter of between 2 nm and 30 nm.
5. (Original) The sustained-release drug delivery device of claim 2 wherein the mesoporous oxide is a triblock copolymer-template-based mesoporous oxide.
6. (Original) The sustained-release drug delivery device of claim 5 wherein the mesoporous oxide is selected from the group consisting of: an oxide of silicon and an oxide of titanium.
7. (Original) The sustained-release drug delivery device of claim 2 wherein the interior surfaces of the interconnected channels are coated with an agent that modifies hydrophobicity or charge.
8. (Original) The sustained-release drug delivery device of claim 7 wherein agent that modifies hydrophobicity or charge comprises a silane coupling agent.

9. (Original) The sustained-release drug delivery device of claim 2 wherein the drug reservoir coating is applied to the surface of the structural element by a method selected from the group consisting of: dip-coating, spray coating, spin-coating and painting.

10. (Original) The sustained-release drug delivery device of claim 2 further comprising a drug loaded within the drug reservoir.

11. (Original) The sustained-release drug delivery device of claim 10 adapted for delivery of the drug for a period of at least 3 days.

12. (Original) The sustained-release drug delivery device of claim 11 adapted for delivery of the drug for a period of at least 7 days.

13. (Original) The sustained-release drug delivery device of claim 12 adapted for delivery of the drug for a period of at least 30 days.

14. (Cancelled)

15. (Original) The sustained-release drug delivery device of claim 10 wherein the drug is an anti-restenotic drug.

16. (Original) The sustained-release drug delivery device of claim 15 wherein the drug is a taxol-derived drug.

17. (Original) The sustained-release drug delivery device of claim 16 wherein the drug is selected from the group consisting of PACLITAXEL, SIROLIMUS, and TACROLIMUS.

18. (Original) The sustained-release drug delivery device of claim 15 wherein the drug delivery device is adapted for implantation into the vascular system of a subject.

19. (Original) The sustained-release drug delivery device of claim 18 wherein the drug delivery device comprises a stent.

20. (Currently Amended) The sustained-release drug delivery device of claim 19 wherein the total amount of drug loaded within the drug reservoir is between ~~50~~ 1 and ~~300~~ 1,000 micrograms per stent.

21. (Original) The sustained-release drug delivery device of claim 2 wherein the drug is selected from the group consisting of: an anti-inflammatory agent, an antimicrobial agent, and antineoplastic agent, and angiogenic agent, an anti-angiogenic agent, a thrombolytic agent, an antihypertensive agent, an anti-arrhythmic agent, a calcium channel blocker, a cholesterol-lowering agent, a psychoactive agent, an anti-depressive agent, an anti-seizure agent, a contraceptives, an analgesics, a bone growth factor, a bone remodeling factor, a neurotransmitter, and an opiate antagonist.

22. – 34. (Cancelled)